JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CLARK, B. B.
Right arrow Articles by MARTIN, S. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by CLARK, B. B.
Right arrow Articles by MARTIN, S. J.
Journal of Pharmacology And Experimental Therapeutics, Vol. 65, Issue 2, 166-174, 1939
Copyright © 1939 by American Society for Pharmacology and Experimental Therapeutics

THE EFFECT OF ATABRINE ON LIVER AND KIDNEY FUNCTION

B. B. CLARK 1, B. COMINOLE 1, and S. J. MARTIN 1

1 From the Department of Physiology and Pharmacology, Albany Medical College, Albany, New York

1. In dogs, atabrine medication with 33 or 66 per cent of the acute m.l.d. daily for 14 and 4 consecutive days respectively resulted in impairment of hepatic function as measured by the bromsulphalein and bilirubin tests.

2. In contrast daily medication with 17 per cent of the m.l.d. for 6 weeks revealed no significant reduction in liver function in 3 of the 4 dogs studied.

3. Chronic dosages of atabrine ranging from 17 to 66 per cent of the m.l.d. administered daily for a period of 42 days gave no evidence of renal damage in 11 of 12 dogs studied.

Submitted on June 25, 1938






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1939 by the American Society for Pharmacology and Experimental Therapeutics.